Centre for Advanced Discovery and Experimental Therapeutics

The Centre for Advanced Discovery and Experimental Therapeutics (CADET) is dedicated to developing new drugs to prevent and treat major diseases such as diabetes and pre-eclampsia.

The innovative £3m facility opened in 2010 and houses state-of-the-art equipment for analysing tissue and blood samples provided by patients.

CADET is the first UK facility to combine a tissue bank, proteomics and metabolomics laboratories all on one site. It also has a team of bioinformatics experts who analyse all the data produced in experiments to identify patterns and trends which could lead to new methods of diagnosis and treatments.

CADET is lead by Professor Garth Cooper, a world-leading expert in this area, who joined the Biomedical Research Centre from New Zealand in 2011. He has published over 200 articles in leading journals, as well as being named as inventor on more than 40 US and European patents.

Cooper discovered the hormone amylin while studying for his doctorate in the UK and went on to invent amylin-replacement therapy for diabetes and founded the NASDAQ-listed US company Amylin Pharmaceuticals.

CADET is based at the Manchester Biomedical Research Centre

Click here to find out more about CADET.